Analytical Data
-
Gene name
Betacellulin/BTC
- Application
-
Alternative Names
BTCProbetacellulin [Cleaved into: Betacellulin; BTC)]
-
Species
Human
-
Source
E. coli
-
Tag
Tag Free
-
Purity
Greater than 98% as determined by SDS-PAGE.
-
Uniprot
P35070
-
Expression Region
32-111aa
-
Protein Length
Partial
-
Molecular Weight
9.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Betacellulin (BTC) is a member of the epidermal growth factor (EGF) family, known for its crucial role in regulating pancreatic beta-cell functions and promoting insulin secretion, making it a significant target in diabetes research. It was initially discovered in pancreatic tissues and has been found to have mitogenic effects on beta-cells, contributing to their proliferation and differentiation. Researchers are particularly interested in BTC due to its potential applications in the treatment of type 2 diabetes, where beta-cell dysfunction is a prominent feature. The ability of BTC to enhance beta-cell survival and function suggests that recombinant BTC proteins could be developed as therapeutic agents. Several studies have explored the molecular mechanisms underlying BTC's action, highlighting its interaction with EGF receptors and downstream signaling pathways that govern insulin biosynthesis and release. Ongoing research is focused on optimizing the production and delivery of recombinant BTC protein, aiming to evaluate its efficacy in preclinical models of diabetes. By enhancing our understanding of BTC’s biological functions and therapeutic potential, these studies aim to pave the way for novel treatments that could restore beta-cell function and improve metabolic control in diabetic patients.
